WE.SPEED.
We are excited to announce the launch of ARENSIA’s Phase 1 patient clinic in Buenos Aires, Argentina!
Our year-long diligence and selection process culminated in an inspiring meeting with Dr. Mario Iván Lugones, the Minister of Health of Argentina. Dr. Lugones’ vision and unwavering commitment to the highest medical standards in patient care and clinical research deeply impressed us. Extensive discussions with local researchers, visits to more than twenty hospitals, and high-level meetings with regulatory authorities have confirmed that Buenos Aires—already a highly valued location for late-phase research—offers the optimal combination of forward-thinking leadership, exceptional physicians, and state-of-the-art medical infrastructure to become a leading hub for sophisticated early-phase clinical trials featuring first-in-class and best-in-class novel therapies.
The newly established 35-day regulatory approval timeline, effective as of last Monday, places Argentina among the fastest and most agile approval environments worldwide.
Buenos Aires, a vibrant metropolitan area of approximately 15 million people, provides access to diverse patient populations ideally suited for pioneering early-phase studies.
With this expansion, we remain committed to ARENSIA’s core mission: providing access to more patients in more countries for novel therapies—and we are proud to extend this opportunity to Argentine patients.
The ARENSIA Phase 1 research clinic is expected to be fully operational by April 2026. Our entry into Argentina marks our first research clinic in Latin America. This is not only a continuation of our 15-year journey of uninterrupted growth — it is a commitment to relentlessly accelerating early-phase timelines across continents.
To find out how ARENSIA Buenos Aires can support and elevate your early-phase portfolio, we invite you to contact us.